ELX-02

Generic Name
ELX-02
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H38N4O10
CAS Number
1375073-95-2
Unique Ingredient Identifier
-
Background

ELX-02 is under investigation in clinical trial NCT03309605 (Phase 1 Study of ELX-02 in Healthy Adult Subjects).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of ELX-02 in Patients With Alport Syndrome

Phase 2
Conditions
Alport Syndrome
Interventions
Drug: ELX-02
First Posted Date
2022-07-07
Last Posted Date
2022-12-20
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT05448755
Locations
🇬🇧

Great Ormond Street Hospital, London, United Kingdom

🇦🇺

Monash Medical Center, Clayton, Victoria, Australia

🇬🇧

Royal Free Hospital, London, United Kingdom

and more 1 locations

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Phase 2
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: ELX-02
Drug: Ivacaftor
First Posted Date
2019-10-22
Last Posted Date
2022-11-22
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
17
Registration Number
NCT04135495
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Stanford School of Medicine, Palo Alto, California, United States

🇺🇸

National Jewish Health, Denver, Colorado, United States

and more 7 locations

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

Phase 2
Completed
Conditions
Cystic Fibrosis
Interventions
Drug: ELX-02
Drug: Ivacaftor
First Posted Date
2019-10-15
Last Posted Date
2023-08-21
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
17
Registration Number
NCT04126473
Locations
🇮🇱

Hadassah Medical Center, Jerusalem, Israel

🇩🇪

Universitätsklinikum Frankfurt, Frankfurt, Germany

🇦🇺

The Royal Prince Alfred Hospital, Camperdown, New South Whales, Australia

and more 6 locations

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Phase 2
Terminated
Conditions
Genetic Disease
Cystinosis
Nonsense Mutation
Interventions
Drug: ELX-02
First Posted Date
2019-08-28
Last Posted Date
2020-05-27
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
3
Registration Number
NCT04069260
Locations
🇨🇦

McGill University Health Center, Montréal, Quebec, Canada

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Phase 1
Completed
Conditions
Impaired Renal Function
Interventions
Drug: ELX-02
First Posted Date
2018-12-14
Last Posted Date
2021-04-13
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
24
Registration Number
NCT03776539
Locations
🇺🇸

Inventiv Health Clinical -Research Pharmacy Unit, Miami, Florida, United States

🇺🇸

University of Miami, Miami, Florida, United States

Phase 1 Study of ELX-02 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Genetic Disease
Nonsense Mutation
Interventions
Drug: Placebo
Drug: ELX-02
First Posted Date
2017-10-13
Last Posted Date
2021-03-16
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
62
Registration Number
NCT03309605
Locations
🇧🇪

SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium

Phase 1 Study of ELX-02 in Healthy Adults

Phase 1
Completed
Conditions
Nonsense Mutation
Genetic Disease
Interventions
Drug: Placebo
Drug: ELX-02
First Posted Date
2017-09-25
Last Posted Date
2023-08-22
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
18
Registration Number
NCT03292302
Locations
🇧🇪

SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Phase 1
Terminated
Conditions
Nonsense Mutations
Genetic Diseases
Interventions
Drug: Placebo
Drug: ELX-02
First Posted Date
2016-06-21
Last Posted Date
2019-10-22
Lead Sponsor
Eloxx Pharmaceuticals, Inc.
Target Recruit Count
42
Registration Number
NCT02807961
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy